We are live on ! Find out more
RA

Rosalind Advisors Portfolio holdings

AUM $249M
1-Year Est. Return 80.12%
This Fund
S&P 500
This Quarter Est. Return
-2.44%
1 Year Est. Return
+80.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$249M
AUM Growth
-$35.6M
Cap. Flow
-$380M
Cap. Flow %
-152.85%
Top 10 Hldgs %
65.95%
Holding
50
New
11
Increased
8
Reduced
11
Closed
14

Top Buys

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$15.7M
2
VOR icon
Vor Biopharma
VOR
+$9.87M
3
CLDX icon
Celldex Therapeutics
CLDX
+$9M
4
XERS icon
Xeris Biopharma Holdings
XERS
+$7.43M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$7.17M

Top Sells

Rank Stock Value
1
ATYR
aTyr Pharma
ATYR
+$13.6M
2
CYTK icon
Cytokinetics
CYTK
+$12.4M
3
CGON icon
CG Oncology
CGON
+$11.3M
4
REPL icon
Replimune Group
REPL
+$10.8M
5
DFTX
Definium Therapeutics
DFTX
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 98.07%

No holdings matched the selected filter criteria.

1 2

Similar funds

TAM
Tabor Asset Management New York $249M AUM 48.59% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
MC
Mount Capital London, United Kingdom $248M AUM 4.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
GWS
Greykasell Wealth Strategies Danville, California $248M AUM 22.08% 1-Year Est. Return
SCM
Segra Capital Management Palm Beach, Florida $248M AUM 65.61% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return

Rosalind Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, Rosalind Advisors held 50 positions worth $249M, down 13% from $285M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Rosalind Advisors withdrew a net $380M in Q1 2026, closing 14 positions and reducing 11 holdings. Its most notable exit was aTyr Pharma, an estimated $13.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier.

Against the trend, Rosalind Advisors opened a new position in Vaxcyte worth $16.9M.

  • Rosalind Advisors's largest Q1 2026 buy was Vaxcyte: 290,000 shares worth $16.9M.
  • Rosalind Advisors added most to Xeris Biopharma Holdings in Q1 2026, an estimated $7.43M increase.
  • Rosalind Advisors's biggest Q1 2026 reduction was CG Oncology, cutting an estimated $11.3M.
  • Rosalind Advisors fully exited aTyr Pharma in Q1 2026, selling an estimated $13.6M.
  • Rosalind Advisors's ten largest holdings make up 66% of its $249M portfolio in Q1 2026.
  • Rosalind Advisors opened 11 new positions and closed 14 in Q1 2026.
  • Rosalind Advisors's portfolio value fell 13% quarter-over-quarter to $249M.

Based on Rosalind Advisors's 13F filing for Q1 2026, filed 14 May 2026.